SCHEMBL6740915

SCHEMBL6740915

OC1(c2ccc3cc[nH]c3c2)CCN2CCCC2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.48
KDM4E B2RXH2 3/20 0.45
ALDH1A1 P00352 3/20 0.45
HSD17B10 Q99714 3/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
CHRNA7 P36544 2/20 0.37
HTR3A P46098 1/20 0.37
ALOX12 P18054 1/20 0.36
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
AHR P35869 1/20 0.35
TYR P14679 1/20 0.35
OPRM1 P35372 2/20 0.34
OPRD1 P41143 2/20 0.34
OPRL1 P41146 2/20 0.34
CCR1 P32246 4/20 0.34
SLC18A3 Q16572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6426403 1.00 HTR6 (0.48) HTR6KDM4EALDH1A1HSD17B10MAPT
SCHEMBL7997497 0.74 HTR6 (0.46) HTR6KDM4EALDH1A1MAPTCCR1
SCHEMBL6744625 0.73 AHR (0.42) KDM4EALDH1A1HSD17B10HPGDCHRNA7
SCHEMBL7006323 0.73 CYP1A2 (0.55) MAPT
SCHEMBL7005001 0.71 HTR1A (0.47) HTR6HTR3A
SCHEMBL7501279 0.71 HTR6 (0.44) HTR6ALDH1A1CHRNA7HTR3ACNR2
SCHEMBL7006270 0.70 HTR1B (0.58) HTR6
SCHEMBL7006286 0.70 HTR1B (0.58) HTR6
SCHEMBL7006099 0.69 SLC6A4 (0.53)
SCHEMBL7010984 0.69 SLC6A4 (0.53)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716837-B1 INDOLE AND INDAZOLE COMPOUNDS NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-04-06 US claimed
EP-1196380-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS Allelix Corp. (CA) 2002-04-17 EP claimed
WO-2001005758-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS ALLELIX CORP. (CA) 2001-01-25 WO claimed
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-08-26 US disclosed
US-6716837-B1 INDOLE AND INDAZOLE COMPOUNDS NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-04-06 US disclosed
EP-1196380-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS Allelix Corp. (CA) 2002-04-17 EP disclosed
WO-2001005758-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS ALLELIX CORP. (CA) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine SCN7A, CNR2, HTR7 HTR6 237/4885KDM4E 2619/4885ALDH1A1 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.